The Priority Review

Regulation Brief

FDA proposes withdrawal of approval for Salerno's Flolipid suspension

The FDA's Center for Drug Evaluation and Research proposes to withdraw approval of NDA 206679 for Flolipid suspension 20 mg/5 mL and 40 mg/5 mL because Salerno Pharmaceuticals has repeatedly failed to file required annual reports. Salerno may request a hearing on the proposal.

Primary source

Federal Register notice, November 18, 2026

Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing

Read the source: Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing federalregister.gov

Machine-summarized from the source above; not independently reported. How we use automation